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ABSTRACT
The interaction between human immunodeficiency
virus type 1 (HIV-1) and RNA silencing pathways is
complexandmultifaceted.Essential forefficientviral
transcription and supporting Tat-mediated transac-
tivation of viral gene expression, the trans-activation
responsive (TAR) element is a structured RNA
located at the 5’ end of all transcripts derived from
HIV-1. Here,wereport thatthis elementis asource of
microRNAs (miRNAs) in cultured HIV-1-infected cell
lines and in HIV-1-infected human CD4+ T lympho-
cytes. Using primer extension and ribonuclease
(RNase) protection assays, we delineated both
strands of the TAR miRNA duplex deriving from a
model HIV-1 transcript, namely miR-TAR-5p and
miR-TAR-3p. In vitro RNase assays indicate that
the lack of a free 3’ extremity at the base of TAR may
contribute to its low processing reactivity in vivo.
Both miR-TAR-5p and miR-TAR-3p down-regulated
TAR miRNA sensor activity in a process that required
an integral miRNA-guided RNA silencing machinery.
miR-TAR-3p exerted superior gene downregulatory
effects, probably due to its preferential release from
HIV-1 TAR RNA by the RNase III Dicer. Our study
suggests that the TAR element of HIV-1 transcripts
releases functionally competent miRNAs upon
asymmetrical processing by Dicer, thereby providing
novel insights into viral miRNA biogenesis.
INTRODUCTION
MicroRNAs (miRNAs) are short 21- to 24-nucleotide (nt)
endogenous RNA species recognized as key regulators of
gene expression that act through the miRNA-guided RNA
silencing pathway (for comprehensive reviews, see 1–4).
Expressed in almost all eukaryotes examined to date,
miRNAs are generated upon processing of miRNA
precursors (pre-miRNAs) by the RNase III Dicer (5,6).
Initial evidences for a role of RNA silencing in host
defense mechanisms against viruses came from studies in
plants. Studying a mechanism known as posttranscrip-
tional gene silencing (PTGS), Hamilton and Baulcombe
(7) detected the presence of viral RNA of  25-nt in virus-
infected plants. These small RNAs were later found to
originate from viral double-stranded RNA (dsRNA)
processing by DICER-LIKE 1 in Arabidopsis (8). Recent
reports suggest that it may play a similar role in human.
Indeed, several studies have shown that viral RNAs, such
as that of Epstein-Barr virus (EBV) (9), mouse gamma-
herpesvirus 68, human cytomegalovirus (10), Kaposi’s
sarcoma-associated herpesvirus (KSHV or HHV8) (10,11)
and simian virus 40 (SV40) (12) harbor secondary stem-
loop structures that represent a source of miRNAs.
Concerning human immunodeﬁciency virus type 1
(HIV-1), its interaction with the RNA silencing pathway
is complex and multifaceted. Synthetic small interfering
RNAs (siRNAs) have been designed against HIV-1 and
used successfully to induce sequence-speciﬁc degrada-
tion of HIV-1 mRNAs and to inhibit viral replication
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certain degree of accessibility of HIV-1 RNA sequences to
the RNA silencing machinery in vivo. Two independent
observations tend to support that notion: (i) a cluster of
cellular miRNAs have been shown to target the 30 ends of
HIV-1 mRNAs and to inhibit virus production in resting
CD4+ T cells; (ii) Drosha and Dicer may contribute to
inhibit HIV-1 replication (14), suggesting that small
RNAs may be released from structured HIV-1 RNAs.
Omoto and colleagues (15) identiﬁed a miRNA residing in
the nef gene (miR-N367) by northern blot, whereas an
siRNA embedded in the env gene region (16) was also
described.
In this study, we report that HIV-1 trans-activation
responsive (TAR) element, a 59-nt stem-bulge-loop RNA
structure located at the 50 end of all HIV-1 mRNA
transcripts, represents a source of regulatory miRNAs that
are functionally competent in RNA silencing processes.
MATERIALS AND METHODS
DNA constructs
The psiRluc (Renilla luciferase) (psiSTRIKE, Promega),
psiNeg vectors and Rluc reporter construct (psiCHECK,
Promega), and their use, have been described previously
(17). psiTAR was constructed by cloning in psiSTRIKE
the HIV-1 TAR sequence. pXP2-LTR-Fireﬂy luciferase
(Fluc) and pXP2-LTRTAR-Fluc constructs were
obtained by cloning either HIV-1 LTR or LTRTAR
of HXB2 (kindly provided by N.R. Landau, The Salk
Institute for Biological Studies, La Jolla, CA, USA) into
the BamHI site of pXP2.
The TAR miRNA sensor constructs were prepared by
cloning a sequence complementary to either TAR nt 1–35
(left arm) or TAR nt 30–59 (right arm) into the SalI
and NotI sites of psiCHECK. pTER+ constructs were
prepared by cloning a sequence encoding either a shRNA
directed against Dicer mRNA, or a deleted region in Rluc
mRNA (used as a negative control), into the pTER
plasmid (kindly provided by M. van de Wetering,
Hubrecht Laboratory, Utrecht, The Netherlands) (18),
as published previously (19).
Cellculture andluciferase activity assays
For TAR miRNA experiments, HEK293 cells were
cotransfected with psiTAR or pXP2-LTR-Fluc, the
miR-TAR-5p or miR-TAR-3p constructs and pLacZ
using calcium phosphate. Mouse embryonic Fmr1 knock-
out (KO) (STEK TSV-40) (17) and wild-type (WT)
(Naı¨ves) (17) ﬁbroblasts were cotransfected with psiTAR
and the miR-TAR-5p or miR-TAR-3p sensor constructs
using calcium phosphate. Cells were harvested 24–48h
later, and luciferase activities were measured, as described
previously (17). b-Gal activity was measured with
Galacto-Light Beta-Galactosidase Reporter Gene Assay
System (Applied Biosystems).
Cultured 293T-REx+pcDNA6TR cells transfected
with either pTER+shDicer or pTER+shNeg were
placed under dual blasticidin (10mg/ml) (InvivoGen) and
zeocin (50mg/ml) (Invitrogen) selection, and clonal cell
lines were isolated. Stably transformed cell lines were
tested for Dicer expression upon induction with 1mg/ml of
doxycyclin (Dox) (Sigma). Selected cell lines shDICER-6,
shDICER-27 and shNEG-13 were pretreated for 12h with
Dox (1mg/ml) and transfected with plasmids coexpressing
the TAR RNA (psiTAR)/miR-TAR-3p sensor or shRluc/
Rluc sensor combinations. Cells were harvested 48h later
and luciferase activities were measured, as described
previously (17).
H9 cells WT and chronically infected with HIV-1 strain
HTLV-IIIMN NIH 1984 (MN cell line) (20) or HTLV-
IIIRF NIH 1983 (RF cell line) (21) were obtained from
Dr Robert Gallo through the NIH AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID,
NIH. For TAR miRNA experiments, 5 10
5 cells were
transfected with 5ng of miR-TAR-5p, miR-TAR-3p or an
unspeciﬁc sensor plasmid, which served as a normalization
control, using Lipofectamine 2000 (Invitrogen). Cells were
harvested 48h later and luciferase activities were mea-
sured, as described previously (17).
Electrophoretic mobility shiftassay
Electrophoretic mobility shift assay (EMSA) analyses
were performed as described previously (5,17). The
recombinant human Dicer preparation used in the present
study was expressed in the Sf9 insect cells used in our
baculovirus expression system and puriﬁed as described by
Provost et al. (5), and was found not to contain Drosophila
Dicer-interacting proteins, such as loquacious (22,23) or
R2D2 (24). Brieﬂy, WT TAR RNA was transcribed
and randomly labeled (a-
32P UTP, Perkin Elmer) by
in vitro transcription using T7 promoter/polymerase
(MEGAshort Script kit, Ambion), puriﬁed by denaturing
PAGE and incubated in the absence or presence
of recombinant human Dicer (5), with or without Tat
(obtained through the NIH AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH) (25),
for 30min on ice prior to EMSA. Dicer TAR RNA
complex formation was analyzed by nondenaturing
PAGE and autoradiography.
In vitro DicerRNase assays
32P-labeled WT TAR RNA and various TAR mutants
(TAR no loop, TAR G/U loop, TAR 10-nt 30 overhang,
TAR bulge other strand, TAR U5 and TAR U3) were
prepared as described in the above section, and incubated
in the absence or presence of recombinant human Dicer
(5) and/or Tat, in a reaction buﬀer containing 20mM
Tris HCl pH 7.5, 5mM MgCl2, 1mM dithiothreitol
(DTT), 1mM ATP, 5% Superase In (Ambion), at 378C
for 1h. The resulting RNA products were analyzed by
denaturing PAGE and autoradiography, as described
previously (5,17).
Production ofvirus stocks and infection
Virus particles were produced by calcium phosphate
transfection of 293T cells with the virus-encoding vector
pNL4-3 (obtained from Dr Malcolm Martin through
the NIH AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH) (26).
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fection of 293T cells with pNL4-3 and an expression
vector coding for the VSV-G full-length envelope protein
(27). Virus stocks were normalized for virion content using
an in-house sensitive double antibody sandwich ELISA
speciﬁc for the major core viral p24 protein (28).
Peripheral blood mononuclear cells (PBMCs) were
obtained from healthy donors and puriﬁed by Ficoll-
Hypaque centrifugation. Human T helper cells (i.e.
CD4+) were negatively isolated from fresh PBMCs
using the CD4+ T cells negative puriﬁcation kit accord-
ing to manufacturer’s instructions (Miltenyi Biotec
Inc., Auburn, CA). CD4+ T cells were activated with
PHA-L (1mg/ml) and IL-2 (30U/ml) for 48h and then
maintained in RPMI containing 10% fetal calf serum
(FCS) (Hyclone Laboratories) and supplemented with
penicillin, streptomycin and IL-2 (30U/ml). Activated
cells were infected with a ﬁxed amount of virus (10ng of
p24 per 10
5 cells) for 4h, washed, and then maintained in
complete RPMI medium. Cells were harvested at 48h
post-infection.
Northern blot analyses
Small RNA (<200nt) fractions were isolated by using the
mirVana miRNA isolation kit (Ambion) from primary
human CD4+ lymphocyte T cells infected with mock or
VSV-G-pseudotyped NL4-3 viruses and analyzed by
northern blotting using
32P-labeled DNA probes recogniz-
ing TAR nt 40–59, mature hsa-miR-16-1 and 5S RNA, as
described previously (5).
RNase protection assays
Small RNA fractions were isolated from (i) H9 cells WT
or chronically infected with HIV-1 strain HTLV-IIIMN or
HTLV-IIIRF, or (ii) HEK293 cells transiently transfected
using calcium phosphate with pXP2-LTR-Fluc, pXP2-
LTRTAR-Fluc, psiTAR or psiNeg vectors and har-
vested 48h later.
RNase protection assays (RPA) were carried out by
using RNA probes complementary to nt 33/64, 40/64,
 5/32 and 3/32 of HIV-1 TAR. The RNA probes were
synthesized from DNA templates by in vitro transcription
using the T7 RNA polymerase (Ambion) and radiolabeled
by random incorporation of a-
32P UTP (Perkin Elmer),
and puriﬁed by denaturing PAGE. The radiolabeled probe
was hybridized with 1.5mg of small RNA for 16h at 578C.
Hybridized RNAs were treated with RNases A/T1
(Ambion) for 30min at 378C, heat inactivated and ethanol
precipitated. Protected RNAs were resuspended into gel
loading buﬀer II, separated by denaturing PAGE (15%)
and visualized by autoradiography.
Primer extension experiments
Small RNA fractions were isolated from HEK293 cells
transiently transfected using calcium phosphate with
pXP2-LTR-Fluc, pXP2-LTRTAR-Fluc, psiTAR or
psiNeg vectors, and harvested 48h later. Brieﬂy, 10mgo f
RNA were hybridized with 50 radiolabeled DNA oligo-
nucleotide complementary to nt 9/23 and 44/61 of TAR
RNA for 15min. After addition of the primer extension
mix [20mM Tris–Cl, 10mM MgCl2, 1.6mM dNTP,
50mg/ml Actinomycin D, 10mM DTT, 2U/ml
SuperScript II Reverse Transcriptase (Invitrogen),
0.1U/ml Superase in (Ambion), pH 8.0], primers were
extended for 1h at 428C. The reaction was stop by phenol/
chloroform extraction and ethanol precipitation. Pellets
were resuspended in gel loading buﬀer II (Ambion) and
separated by denaturing PAGE (15%). The extended
primers were visualized by autoradiography.
RESULTS
HIV-1 TAR RNA isprocessed by Dicer invitro
Exploring speciﬁc aspects of the interaction between
HIV-1 and the host miRNA-guided RNA silencing
pathway, we initially asked whether HIV-1 RNA would
be susceptible to Dicer cleavage. Essential for eﬃcient
viral transcription, HIV-1 TAR element shows important
structural similarities with the hsa-let-7a-3 pre-miRNA
(Figure 1A), which can be processed into miRNA by
recombinant human Dicer in vitro (5). When incubated
with
32P-labeled TAR RNA, Dicer was able to bind (see
Figure 1B, left panel) and cleave (see Figure 1B, right
panel) it into  23- to 24-nt miRNA products, making of
HIV-1 TAR a potential Dicer substrate.
HIV-1 TAR element is the target of the viral
transactivating Tat protein, which is expressed during
the course of HIV-1 infection and known to act at the
RNA level to enhance viral gene expression by >100-fold
(29). We thus examined whether Tat could shield TAR
RNA and prevent its processing by Dicer. To this end, we
determined the experimental conditions under which all
TAR RNA is bound by Tat. However, the TAR RNA
precomplexed with saturating amounts of Tat remained
susceptible to Dicer cleavage (I. Plante and P. Provost,
unpublished data).
HIV-1 TAR element is asource ofmiRNAs in vivo
These in vitro ﬁndings were to be interpreted with caution,
since the contribution of other proteins and cellular
components could not be taken into account. In order
to circumvent these issues and to conﬁrm that HIV-1 TAR
is a source of miRNAs under more physiological
conditions in vivo, we made use of mock- or NL4-
3-infected primary human CD4+ T lymphocytes and
investigated their small RNA content by northern blot.
Previously shown to be expressed in T lymphocytes (30),
we were able to detect the mature form of miR-16-1 (see
Figure 2A, middle panel, right lane) as well as that of its
pre-miR-16-1 and pri-miR-16-1 precursors (I. Plante and
P. Provost, unpublished data). Noticeably, the level of
miR-16-1 remained unchanged in NL4-3- versus mock-
infected primary human CD4+ T lymphocytes (see
Figure 2A, middle panel, left lane versus right lane).
This is in contrast with a previous study by Bennasser
et al. (31), who have reported speciﬁc down-regulation of
miR-16 levels in HeLa cells overexpressing HIV-1 TAR
RNA, a discrepancy that may be accounted for by the
diﬀerence in the experimental settings (i.e. primary human
cells versus an established cell line).
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from HIV-1 TAR RNA in vivo allowed the detection of an
RNA product slightly longer than the 22-nt miR-16-1 in
NL4-3-, but not in mock-infected, primary human CD4+
T lymphocytes (see Figure 2A, upper panel). Additional
bands speciﬁc to NL4-3-infected cells that may correspond
to cleavage intermediates of TAR were also observed.
These results opened the possibility that HIV-1 TAR
RNA may represent a source of miRNAs in vivo.
In order to conﬁrm these ﬁndings, we used a diﬀerent
experimental approach and analyzed the small RNAs
population of two HIV-1-infected cell lines by RPA.
When assessing the presence of a miRNA deriving from
the left arm of TAR with probe  5/32, a protected RNA
species of 27nt was detected (see Figure 2B, upper panel).
Whereas the use of probe 33/64 allowed the detection of
 28–31nt RNA species speciﬁc to HIV-1-infected cells
(see Figure 2B, lower panel). These results suggest that
miRNAs may originate from both arms of HIV-1 TAR
RNA in vivo.
Delineation of themiRNAs released from HIV-1 TAR
To get a better deﬁnition of these viral miRNAs, we
performed primer extension in combination with RPA.
Using these approaches, we analyzed small RNA pre-
parations derived from HEK293 cells expressing a
reporter gene placed under the control of either the
Figure 1. HIV-1 TAR RNA is bound and cleaved by recombinant
Dicer into  23–24-nt miRNA products in vitro.( A) Structural
similarities between HIV-1 TAR RNA and the hsa-let-7a-3 pre-
miRNA. The arrows indicate the Dicer cleavage sites. (B) Left,
EMSA.
32P-labeled TAR RNA was incubated in the absence or
presence of Dicer, and the formation of Dicer TAR complexes was
analyzed by nondenaturing PAGE and autoradiography. (B) Right,
Dicer RNase assays.
32P-labeled TAR RNA was incubated in the
absence or presence of Dicer with MgCl2. The samples were analyzed
by denaturing PAGE and autoradiography. M, indicates a 10-nt RNA
size marker.
Figure 2. Detection of miRNAs released from TAR in HIV-1-infected
cells. (A) Northern blot analysis of small RNAs (<200nt) isolated from
primary human CD4+ T lymphocytes infected for 48h with VSV-
G-pseudotyped HIV-1 (NL4-3 clone) or mock. A 50 end labeled probe-
recognizing nt 40–59 of HIV-1 TAR (upper panel) was hybridized and
detected by autoradiography. The membrane was subsequently probed
for the presence of the 22-nt miR-16-1 (middle panel) and of 5S RNA
(lower panel). (B) RPA. Small RNAs (<200nt) isolated from H9 cells
wild-type ( ) or chronically infected with HTLV-IIIMN NIH 1984
(MN) or HTLV-IIIRF NIH 1983 (RF) HIV-1 strains were analyzed by
RPA. Protected RNAs were separated by denaturing PAGE (15%) and
visualized by autoradiography. Open arrowheads indicate RNA species
expected to be protected by probe  5/32 (upper panel) and 33/64
(lower panel), respectively.
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element (LTRTAR-Luc).
Reactions of primer extension performed with an
oligonucleotide complementary to nt 61–44 (probe
44/61) yielded a 24-nt TAR-speciﬁc band (see Figure 3A,
left panel, ﬁlled arrowhead). Elongation of probe 44/61 by
6nt indicates that nt 38 may represent the 50 end of the
miRNA. Considering the premise that nt 58 of TAR is
part of the miRNA, this observation is supported by
(i) the 26-nt RNA species obtained by using probe 33/64
(see Figure 3A, center panel) and (ii) a 22-nt band
obtained by using probe 29/58 (I. Plante, D.L. Ouellet and
P. Provost, unpublished data). A 50 end formed by nt 34,
as suggested by the 28-nt RNA band obtained upon
extension of probe 44/61 (see Figure 3A, left panel, open
arrowhead), is less likely, since it is not supported by
concurrent RPA analysis.
Experimental support for nt 60 as the 30 end of the
miRNA originating from the right arm of TAR comes
from (i) a 21-nt RNA obtained by the use of probe 40/64,
assuming that nt 40 is part of the miRNA (see Figure 3A,
right panel, ﬁlled arrowhead), and (ii) an 18-nt fragment
observed when using probe 43/71, assuming that nt 43 is
part of the miRNA (I. Plante, D.L. Ouellet and P.
Provost, unpublished data). Together, the results of our
analyses are consistent with a 23-nt RNA being derived
from nt 38–60 of the right arm of TAR.
miRNAs are known to be contained within miRNA
duplexes that result from Dicer processing of miRNA
precursor molecules. Analysis of primer extension reac-
tions performed with an oligonucleotide complementary
to nt 23–9 revealed a single band of 20nt speciﬁc to TAR
(see Figure 3B, left panel), pointing towards nt 4 as the
50 end nt. RPA analyses using two diﬀerent probes
covering nt  5 to 32 and nt 3–32 of TAR both revealed
protected RNAs as a major band of 25nt (see Figure 3B,
center and right panels). Together, these results are in
agreement with the generation of a 24-nt RNA originating
from the left arm of TAR and spanning nt 4–27.
The consensus miRNA duplex sequence derived from
the HIV-1 TAR element, as deduced from our analyses, is
shown in Figure 3C. In compliance with current conven-
tion, the miRNA derived from the left arm of the TAR
stem has been named miR-TAR-5p, whereas that origi-
nating from the right arm of TAR has been deﬁned as
miR-TAR-3p.
Structural determinants ofHIV-1 TAR RNA
processing by Dicer
We then wished to identify the structural determinants of
TAR RNA processing in Dicer RNase assays in vitro.
Figure 3. Delineation of the miRNA duplex derived from the
HIV-1 TAR element. (A and B) Small RNAs (<200nt) isolated
from HEK293 cells, transfected with or without pXP2-LTR-Fluc or
pXP2-LTRTAR-Fluc, were analyzed by primer extension and RPA.
(A) miR-TAR-3p. Left, Primer extension analysis using a deoxyribo-
nucleotide complementary to TAR nt 61–44, and run in parallel with
DNA size markers. The extended products were analyzed by
denaturing PAGE. Right, RPA using RNA probes directed against
HIV-1 TAR nt 33/64 and nt 40/64, and run in parallel with RNA size
markers. Protected small RNAs were analyzed by denaturing PAGE.
Open arrowheads indicate RNA species not supported by concurrent
RPA analysis, whereas ﬁlled arrowheads indicate the RNA bands
considered to establish the consensus TAR miRNA duplex. (B) miR-
TAR-5p. Left, Primer extension analysis using a deoxyribonucleotide
complementary to nt 23–9. Right, RPA using RNA probes directed
against HIV-1 TAR nt  5/32 and nt 3/32. Filled arrowheads indicate
the RNA bands considered to establish the consensus TAR miRNA
duplex. (C) The consensus miR-TAR-5p:miR-TAR-3p duplex derived
from HIV-1 TAR. The arrows indicate the cleavages sites deduced from
primer extension and RPA results.
Nucleic Acids Research, 2008, Vol. 36, No. 7 2357Stem-bulge-loop RNAs are processed by members of the
RNase III family of enzymes, such as Rnt1p (32) and Pac1
(33), through a mode of recognition involving their loop
and bulge. To evaluate the importance of the loop, we
prepared a TAR RNA substrate lacking the loop sequence
(Figure 4A). The resulting TAR RNA duplex was cleaved
by Dicer in vitro (Figure 4B), suggesting that the presence
of the loop is not a prerequisite for HIV-1 TAR
processing.
The RNase III Rnt1p exhibit a certain degree of
speciﬁcity for RNA substrates bearing AGNN tetraloop,
which led us to investigate whether this property is also
displayed by the RNase III Dicer. When incubated with
Dicer, a G/U loop TAR RNA mutant was cleaved as
eﬃciently as the wild-type sequence (Figure 4C).
A diﬀerence, however, was the appearance of a  10-nt
RNA species that may originate from the
32P-labeled,
U-rich loop element of the G/U loop mutant (see
Figure 4C, last four lanes). These data indicate that
TAR RNA processing by Dicer depends neither on the
presence nor the sequence of its loop.
We next addressed the contribution of the bulge, a
structural element commonly present near the loop of pre-
miRNAs, by preparing a substrate in which the 3-nt bulge
was transferred to the same position on the other strand,
i.e. from the left arm to the right arm of TAR. Analysis of
the Dicer RNase reactions by denaturing PAGE revealed
a diﬀerence in the pattern of small RNAs generated
(Figure 4D). This observation suggests that the position-
ing of the bulge on either arm of the TAR stem may be
critical in determining the sequence of the miRNAs
released by Dicer.
We then questioned the nature and contribution of the
base of the TAR stem. HIV-1 TAR RNA diﬀers from pre-
miRNA substrates, since its 30 extremity is not available,
rather extending into the 50 LTR of HIV-1 mRNAs.
Therefore, we mimicked the unavailable 30 extremity of
the HIV-1 TAR RNA by prolonging the 2-nt 30 overhang
to 10nt. This modiﬁcation markedly decreased the
susceptibility of TAR to cleavage by Dicer in vitro
(Figure 4E). The predicted structure of the TAR substrate,
as analyzed by MFOLD (34), was preserved (P. Landry
and P. Provost, unpublished data), excluding the possibi-
lity that global structure rearrangements inﬂuenced our
data. These results suggest that the extended 30 extremity
of TAR, such as that encountered in the HIV-1 50 LTR,
may hamper its processing by Dicer.
miR-TAR-5p and miR-TAR-3p arefunctional in gene
regulationin vivo
We then asked if the miRNAs derived from TAR are
functional and can exert gene regulatory eﬀects in human
cells. This aspect was initially addressed by designing a
TAR expression construct (psiTAR) based on the
psiSTRIKE vector backbone. In preliminary experiments,
the RPA patterns of the miRNAs derived from psiTAR,
obtained by using probes  5/32 and 33/64, were similar to
those obtained upon LTR-Fluc (D.L. Ouellet, I. Plante
and P. Provost, unpublished data). These data validated
psiTAR as a TAR miRNA expression vector suitable for
the assessment of miR-TAR-5p and miR-TAR-3p func-
tion in cultured human cells.
The mammalian expression vectors psiTAR and
pXP2-LTR-Fluc were then used in TAR miRNA func-
tional assays established in HEK293 cells, as depicted
Figure 4. Structural determinants of HIV-1 TAR RNA processing by
Dicer. (A) Structure of the HIV-1 TAR RNA variants. The structure of
wild-type TAR RNA is shown in Figure 1A. (B–E)
32P-labeled TAR
RNAs with (wild-type, WT) or (B) without the loop (no loop), (C) with
a G/U loop, (D) with the bulge transposed to the right arm (bulge
other strand) or (E) with a 2-nt (2-nt 30 overhang) or 10-nt (10-nt 30
overhang) extension at the 30 end were incubated in the absence or
presence of recombinant human Dicer with MgCl2. The cleavage
products were analyzed by denaturing PAGE and autoradiography.
2358 Nucleic Acids Research, 2008, Vol. 36, No. 7in Figure 5A. In these assays, HIV-1 TAR was expressed
either in the form of an isolated miRNA precursor (via
psiTAR) or embedded within its natural 50 LTR context
in a model HIV-1 LTR-Fluc transcript (via pXP2-LTR-
Fluc). The gene regulatory eﬀects of the TAR miRNAs
was monitored through TAR miRNA sensor constructs
speciﬁc to either miR-TAR-5p or miR-TAR-3p. As shown
in Figure 5B, TAR expression induced a dose-dependent
down-regulation of both TAR miRNA sensors, suggesting
that the TAR miRNAs entered the miRNA-guided RNA
silencing pathway. The degree of inhibition induced by
miR-TAR-3p was noticeably greater than that induced by
miR-TAR-5p (see Figure 5B, right versus left panels).
Next, we wished to determine the functionality of the
miRNAs derived from TAR when located at the 50 end of
a model HIV-1 mRNA transcript. For that purpose, we
measured TAR miRNA sensor activity in the presence of
pXP2-LTR-Fluc, and normalized the results with the
pXP2-LTRTAR-Fluc vector lacking the TAR element
so to visualize the changes speciﬁcally related to miRNAs
derived from TAR. In these experiments, we observed
a decrease in reporter gene expression induced by the
TAR-containing model HIV-1 transcript (Figure 5C).
Again, the eﬀects mediated by miR-TAR-3p were more
pronounced than its miR-TAR-5p counterpart (see
Figure 5C, right versus left panels). These results attest
to the functional competence of the TAR miRNAs
derived from the HIV-1 50 LTR in gene regulatory
processes of the host cell.
Whether miR-TAR-5p and miR-TAR-3p are produced
and can exert gene regulatory eﬀects in HIV-1-infected
cells was examined by assessing the activity of their
respective sensor constructs in H9/HTLVIIIMN and H9/
HTLVIIIRF cell lines. As shown in Figure 5D, expression
of the reporter gene coupled with a sensor speciﬁc to miR-
TAR-3p was decreased by  20% in the MN cell line
(P<0.05), as compared with a reporter gene coupled with
an unspeciﬁc sensor. When compared with RF cells, the
degree of down-regulation was slightly more pronounced
in the MN cell line, which also express more p24 proteins.
These results indicate the presence in these virus-infected
cells of miRNAs derived from HIV-1 TAR element at
levels suﬃcient to be detected in a sensor-based reporter
gene system.
Diceris requiredfor TAR miRNA function in vivo
Taken together, our results militate for the involvement of
Dicer in the gene regulatory roles of HIV-1 TAR miRNAs
Figure 5. The miRNAs released from the HIV-1 TAR element function
in gene regulatory processes in vivo.( A) Experimental scheme of the TAR
miRNA functional assays. (B) HEK293 cells were cotransfected with
psiTAR and a TAR miRNA sensor construct in which the Rluc reporter
gene is coupled with a BS perfectly complementary to the miR-TAR-5p
or miR-TAR-3p sequence. Results are expressed as mean SEM.
(n=6 experiments, in duplicate).
 P<0.05 or
  P<0.01 versus 0.25ng
psiTAR (one-way ANOVA). (C) HEK293 cells were cotransfected with
pXP2-LTR-Fluc, a TAR miRNA sensor construct and pLacZ. Results
of Rluc activity were normalized with b-galactosidase activity, and
expressed as a percentage of Rluc activity obtained with pXP2-
LTRTAR-Fluc lacking the TAR element. Results are expressed as
mean SEM (n=6–9 experiments, in duplicate).
 P<0.05 versus 100ng
pXP2-LTR-Fluc (one-way ANOVA). (D) H9 cells infected with HIV-1
strain HTLV-IIIMN or HTLV-IIIRF were transfected with miR-TAR-5p
or miR-TAR-3p sensor construct and harvested 48h later. Results of
Rluc activity were normalized with those obtained from the unspeciﬁc
sensor plasmid. Mean SEM (n=2 in duplicate).
 P<0.05 versus the
unspeciﬁc sensor (Student’s t-test). The levels of HIV-1 p24 protein
released from either HTLV-IIIMN or HTLV-IIIRF cell lines into the
medium were measured by ELISA.
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and shDICER-27 cell lines, which have been engineered
to conditionally express shRNAs directed against Dicer.
A partial, but sustained, down-regulation of Dicer
expression was achieved upon Dox treatment, as assessed
by western blot (Figure 6A). This coincided with a
signiﬁcant impairment of reporter gene repression
mediated by miR-TAR-3p, as compared with untreated
cells or shNEG-13 cells expressing basal levels of Dicer
(Figure 6B). A comparable defect in RNA silencing was
observed when examining Rluc sensor regulation
mediated by shRluc expression (Figure 6C). Extending
our in vitro data on the ability of recombinant human
Dicer to release miRNAs from HIV-1 TAR RNA, these
ﬁndings conﬁrm a role for Dicer in the regulation of gene
expression mediated by TAR miRNAs in vivo.
FragileX mental retardation proteinmediates the
repressive actionof TAR miRNAs
The involvement of the miRNA-guided RNA silencing
machinery in these regulatory events was also conﬁrmed in
cells lacking fragile X mental retardation protein (FMRP),
a component of the eﬀector RNP complex that have been
reported to facilitate RNA targeting by Dicer-derived
miRNAs and to be required for eﬃcient RNA silencing in
mammalian cells (17). To this end, we employed the STEK
TSV-40 cell line (17), which we previously validated as a
functional representative of four diﬀerent Fmr1 KO cell
lines (17), in parallel with an isogenic cell line established
from wild-type mice (Naı¨ves) (17). In addition to correct
for cell-to-cell variability, the use of a second reporter gene
(Fluc) in our assays allowed us to examine the function of
FMRP pertaining to small RNA-mediated RNA silen-
cing. This was particularly important considering that
FMRP could act as a negative regulator of translation
(35). Expression of TAR in wild-type murine ﬁbroblasts
led to a dose-dependent decrease of both miR-TAR-5p
and miR-TAR-3p sensor activities (Figure 7A and B).
However, silencing of the TAR miRNA sensors was
impaired in cells lacking FMRP, indicating the require-
ment of an integral eﬀector complex to mediate TAR
miRNA function in vivo.
Figure 7. FMRP is required for optimal miR-TAR-5p and miR-
TAR-3p function in vivo.( A and B) Fmr1 KO (TSV-40) and wild-type
(Naı¨ves) cells were transfected to coexpress TAR RNA (psiTAR) and
(A) miR-TAR-5p sensor, or (B) miR-TAR-3p sensor construct. Results
are expressed as mean   SEM (n=6 experiments, in duplicate).
 P<0.05 or
  P<0.01 versus Naı¨ves (Student’s t-test).
Figure 6. Dicer is required for the gene regulatory eﬀects of miR-
TAR-3p. (A) Immunoblot (IB) analysis showing Dicer protein down-
regulation induced upon Dox treatment (upper panels), in parallel with
actin control (lower panels). (B and C) Stable 293T-REx+pcDNA6TR
cells conditionally expressing a shRNA directed against Dicer mRNA
(shDICER-6 and shDICER-27), or a deleted region in Rluc mRNA
(shNeg-13), were induced with 1mg/ml of Dox for 12h (+Dox) before
transfection with plasmid expressing the (B) TAR RNA/miR-TAR-3p
sensor, or (C) shRluc/Rluc sensor combination. Mean SEM (n=4
experiments, in duplicate).
 P<0.05,
  P<0.01 or
   P<0.005 versus
prior induction ( Dox) (Student’s t-test).
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processing of HIV-1 TAR RNA
During the course of our studies, we observed that the
activity of the miR-TAR-3p miRNA sensor was system-
atically repressed more than the miR-TAR-5p miRNA
sensor upon TAR expression (Figures 5B, C and 7),
consistent with a preferential accumulation of the mature
miR-TAR-3p in vivo. In order to get further insights into
HIV-1 TAR RNA processing into miR-TAR-3p by Dicer,
we prepared three substrates designed to monitor the
formation of RNA products containing the left arm, the
loop and/or the right arm of TAR. This was accomplished
by positioning the Us of paired nt combinations on either
the left arm (TAR U5) or the right arm (TAR U3)
of TAR, while preserving its nt content, base pairing
and predicted secondary structure (MFOLD analysis,
P. Landry and P. Provost, unpublished data), as shown in
Figure 8A. Analysis of the Dicer RNase reactions showed
that processing of the TAR U5 and TAR U3 mutants was
comparable, but more eﬃcient than that of the TAR G/U
loop mutant, as suggested by the decreased intensity of the
bands corresponding to the substrate (denoted a, using a
single-letter code) (see Figure 8B, upper panel) and the
associated increase in the 10-nt, loop-containing RNA
species (denoted e) (see Figure 8B, lower panel). It is thus
possible that the interversion of the U paired nt
combinations may have slightly inﬂuenced its suscept-
ibility to Dicer cleavage.
Nevertheless, informative diﬀerences in the band
patterns and intensities were noted upon Dicer processing
of the TAR U5 and TAR U3 RNA mutants, the latter of
which was otherwise similar to the TAR G/U loop RNA
(see Figure 8B, lower panel). First, enrichment of the TAR
miRNA bands (denoted d) upon labeling of the right arm
of the TAR stem, conjugated with the impoverishment of
band d associated with unlabeling of the right arm of the
TAR stem, is suggestive of its presence in RNA species
d. Second, following a similar reasoning, appearance of
RNA species b upon labeling of the left arm of TAR is
indicative of its presence in this intermediate RNA species.
Third, the length of RNA species b diﬀers from that of
RNA species d by  10nt (i.e. the length of RNA species
e), which likely contains the loop sequence (please refer to
Figure 4C) released upon Dicer cleavage of both arms in
the upper part of the TAR stem (please refer to Figure 3C
for the predicted cleavage sites). RNA species b is thus
likely composed of the left arm of TAR with the loop.
Fourth, in accordance with this inference, the very low
intensity of RNA bands b upon TAR U3 RNA processing
is compatible with the absence of intermediate RNA
species comprised of the loop and the right arm of TAR.
Fifth, appearance of RNA species c upon labeling of the
left arm of TAR and its size of  24nt suggest that it may
be an RNA intermediate from which nt 1–3 of the left arm
of TAR are removed to yield miR-TAR-5p. Collectively,
our observations support the concept by which miR-
TAR-3p would be released from the TAR element in a
process yielding the miR-TAR-5p-loop as an intermediate
RNA species.
DISCUSSION
Known to alter the expression of thousands of genes (36),
HIV-1 has been shown recently to alter the expres-
sion proﬁle of cellular miRNAs. Comparing HIV-
1-infected versus noninfected cells by microarray analysis,
Figure 8. Asymmetric release of miR-TAR-3p upon HIV-1 TAR
processing by Dicer. (A) Structure of the TAR G/U loop RNA or
modiﬁed G/U loop RNA mutants, in which the A-U and G U base
pairs of the TAR stem were preserved, but positioned to have all
the
32P-labeled Us either on the left arm (TAR U5) or the right arm
(TAR U3). (B) These TAR substrates were incubated in the absence or
presence of recombinant human Dicer with MgCl2. The cleavage
products were analyzed by denaturing PAGE and autoradiography.
The RNA species detected upon in vitro processing by Dicer contain
speciﬁc TAR RNA structures and are denoted as follows: a, TAR
RNA substrate; b, left arm+loop; c, long left arm precursor of
miR-TAR-5p; d, right arm; e, loop.
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up-regulated, whereas others were down-regulated by
HIV-1. These ﬁndings are not compatible with a general
shutdown or stimulation of the miRNA-guided RNA
silencing machinery by the virus and rather argue for an
alternative mechanism to explain how speciﬁc genes and
miRNAs are modulated by HIV-1.
Initial studies aimed at investigating the existence of
virus-derived miRNAs, through the use of small RNA
cloning methods, were unable to provide experimental
evidences in the case of HIV-1. In a study by Pfeﬀer et al.
(10), no miRNA of viral origin was found among 1540
small RNA sequences cloned from HeLa cells stably
expressing CD4 and CXCR4, and infected with HIV-1,
isolate Bru (LAV1). On the other hand, two independent
groups have obtained positive signals from the use of
northern blotting, compatible with small HIV-1 RNAs
(15,16). Here, we characterized and delineated miRNAs
originating from the HIV-1 TAR element by making
use of northern blotting, primer extension and RPA.
As shown for SV40, this latter method may be suitable,
better adapted and more sensitive for the detection of viral
miRNAs (12).
Why had HIV-1 TAR miRNAs eluded detection for so
long? First, low expression levels of some viral miRNAs
may render their isolation by cloning methods diﬃcult
among the more abundant cellular ribosomal RNAs,
transfer RNAs and miRNAs. This is consistent with the
facts that miRNA cloning frequency reﬂects miRNA
abundance and that miRNAs cloned in a single copy may
be more diﬃcult to detect (37). Second, viral and cellular
proteins interacting with the TAR element within the
50 LTR of HIV-1 mRNAs likely decrease its vulnerability
to processing by RNases III. Third, HIV-1 TAR element
may partially escape RNases III processing by adopting
alternative conformations, such as one called TAR31,
which is functionally similar but requires only 31nt to
form (38). Fourth, the lack of a free 2-nt 30 overhang at the
base of TAR in HIV-1 mRNA transcript may hamper its
processing, as demonstrated by the marked decrease
in TAR RNA processing by Dicer upon extension of its
30 overhang sequence from 2 to 10nt. Finally, we cannot
exclude the possibility that the TAR miRNAs are
modiﬁed on the 20 hydroxyl of the terminal ribose,
which would signiﬁcantly hamper the cloning eﬃciency
of these modiﬁed small RNAs, as experienced in plants
(39). On the other hand, it is known that the HIV-1
promoter directs, in the absence of Tat, the synthesis of
another class of short nonpolyadenylated transcripts with
heterogeneous 30 ends located around position +59 (40).
These transcripts may thus represent potential substrates
for Dicer and argue for a speciﬁc sub-population of TAR
as an alternative source of HIV-1 miRNAs.
When examining the TAR miRNA sequences eluci-
dated by primer extension and RPA, we noticed a nt bias
at the 50 end of both miR-TAR-5p and miR-TAR-3p. The
presence of a U at this position is in agreement with the
preference of the RNases III Drosha and Dicer to cleave
on the 50 side of a U. Likely long enough to be recognized
and processed by the RNase III Dicer, the TAR element
may be too short for Drosha, whose pri-miRNA
substrates typically contain a stem of  3 helical turns
( 33bp) (41). Moreover, TAR miRNAs do not result
from cleavage  11bp away from the single-stranded
junction at the base of TAR, as would be expected from
the Drosha DGCR8 complex (42). Experimental data
rather support the speciﬁc involvement of Dicer in HIV-1
TAR RNA processing. First, TAR RNA was eﬃciently
cleaved by recombinant Dicer in vitro. Similar ﬁndings
were reported recently by Klase et al. (43). Second, the size
of the TAR RNA products ( 23–24nt) detected in vivo
correlates with that expected for RNAs issued from Dicer
cleavage. Third, TAR RNA was processed into a miRNA
duplex, a recognized Dicer signature. The most thermo-
dynamically favorable pairing of the TAR miRNA duplex
diﬀers from the sequence structure located in the
unprocessed TAR and exhibits two 3-nt 30 overhangs
(D.L. Ouellet, I. Plante and P. Provost, unpublished data).
This opens the possibility of a pairing rearrangement
within the duplex upon removal of the neighboring base
pairs and sequences in the precursor molecule.
The extremities of some viral miRNA duplexes seem to
diverge from the general 2-nt 30 overhang rule established
for endogenous miRNAs. Like the TAR miRNA duplex,
miRNAs derived from SV40 (12) and KSHV (11) also
exhibit atypical 3-nt 30 overhangs. Computational posi-
tioning of mature KSHV miRNA sequences also revealed
duplexes bearing 30 overhangs as short as 1nt (11). The
discrepancies between the viral and endogenous miRNAs
may bear the signs of subtle processing irregularities,
possibly related to the adaptive capacity of the RNA
silencing components to recognize and process internal
viral RNA structures like miRNA precursors. Initially
reported in Zhang et al. (44), Dicer excision of miRNAs
from internal sites is not infrequent, as the long CAG and
CUG repeats found within their natural context in
transcripts from mutant genes involved in diseases such
as myotonic dystrophy type 1, Huntington’s disease and
spinocerebellar ataxia type 1 are eﬃciently cleaved by
Dicer (45).
Mechanistically, endogenous substrate recognition by
Dicer has been proposed to involve anchoring of the pre-
miRNA 2-nt 30 overhang in the pocket formed by its
central PAZ domain (6,46). Furthermore, the 2-nt over-
hang is measured by the alignment of the Dicer RNase III
domains rather than by the distance between active
residues on one peptide chain, whereas the length of the
product ( 21nt) is determined by the distance between the
PAZ domain and the active site (6). Flanked by a single-
stranded RNA sequence on its 30, TAR RNA processing
may be suboptimal, perhaps less accurate. In support to
this possibility is a study by Vermeulen et al. (47)
reporting that shifts in Dicer cleavage sites result from
dissimilar processing of substrates bearing overhangs of
diﬀerent lengths. In addition, folding of the TAR element
itself may force Dicer dimers to adopt a slightly modiﬁed
conﬁguration. The 3-nt bulge, in particular, has been
shown to introduce a bend of  508 into the a helical RNA
structure of TAR (48), which otherwise exhibits a certain
degree of ﬂexibility. These structural constraints may
explain the length of the TAR miRNAs, the nature
of the overhangs generated and the relative degree
2362 Nucleic Acids Research, 2008, Vol. 36, No. 7of heterogeneity of the cleavage sites determined for
miR-TAR-3p (please refer to the open arrowheads in
Figure 3A).
Transactivation by the viral protein Tat is severely
compromised upon introduction of G/U mutations in the
loop of the TAR element (49). When studied in parallel
with the wild-type TAR, however, the G/U loop TAR
mutant was processed with similar eﬃciencies by Dicer
in vitro. These observations support the notion that the
TAR structure that evolved to support transactivation by
Tat remains susceptible to cleavage by Dicer, possibly
reﬂecting the inability of TAR to escape from Dicer
surveillance. Evocative of the rapid adaptive evolution of
the antiviral pathway in Drosophila (50), this ongoing
interaction between HIV-1 and Dicer may be constantly
shaping the antiviral functionalities of the host RNA
silencing machinery.
When interpreting the results obtained from Dicer
RNase assays in vitro, the caveat has to be taken into
account that recombinant human Dicer exhibits low
processive activity in vitro (5,44), a characteristic that
has been attributed to the product remaining bound to the
enzyme (44). In more recent studies, Dicer has been shown
to operate with TRBP within a pre-miRNA processing
complex (51,52) and to interact with Ago2 (53), another
component of miRNA-containing ribonucleoprotein
(miRNP) complexes (54). Although it has been reported
to facilitate pre-miRNA processing in vitro (52), the role of
TRBP in modulating Dicer function remains largely
undeﬁned. It may be analogous to that played by
DGCR8 within the Drosha DGCR8 complex, in which
DGCR8 may interact directly and speciﬁcally with pri-
miRNAs, and proposed to function as a molecular
anchor that determines the Drosha cleavage sites (41).
Alternatively, TRBP may contribute to releasing the
miRNA product from Dicer and improving biosynthesis
of miR-TAR-5p in vivo.
Data obtained from Dicer knockdown and FMRP
KO cells show that TAR miRNAs are recognized and
channelled through the miRNA-guided RNA silencing
pathway. Our TAR miRNA sensor activity assays
revealed the miRNAs residing within the TAR element
of HIV-1 are functional, as both miR-TAR-5p and miR-
TAR-3p exerted downregulatory eﬀects on gene expres-
sion, and that these eﬀects were optimal in the presence of
Dicer and FMRP. Together, our ﬁndings are compatible
with TAR miRNAs being extracted from the HIV-1 TAR
element by Dicer to be subsequently incorporated into
active miRNP complexes in vivo, in which FMRP may act
to facilitate their annealing to mRNAs bearing sites of
perfect or imperfect complementarity. Whether Dicer
mediates action of TAR miRNAs by acting also within
miRNP eﬀector complexes in vivo remains to be
determined.
Although indicative of the presence of miRNAs derived
from HIV-1 TAR element, the response of our sensor
constructs in HIV-1-infected cells was relatively modest
and less pronounced than that observed in cotransfected
293 cells. This observation may be related to the fact that
cells infected with the virus express low physiological
levels of TAR RNA, in contrast with vector-based,
U6 promoter-driven overexpression of TAR RNA.
In addition, expression in these cells of the viral TAR
RNA binding Tat protein, which has been proposed as a
suppressor of RNA silencing (16), may have hampered
Dicer processing of TAR RNA and contributed to
attenuate the signal expected. Although a recent study
reported that physiological levels of HIV-1 Tat neither
inhibited the RNA silencing machinery of infected cells
nor induced the accumulation of pre-miRNAs as would be
predicted for an inhibitor of Dicer function (55).
As assessed in mRNA target regulation, the silencing
properties of miR-TAR-3p were slightly superior than
those of miR-TAR-5p, supporting a relative functional
asymmetry. This may be related to diﬀerences in the
thermodynamic stability of the miRNA duplex extremi-
ties, as reported in Drosophila where R2D2 has been
shown to act as a protein sensor for siRNA thermo-
dynamic asymmetry (56). At that level, the human
miRNA-guided RNA silencing machinery may diﬀer
from the ﬂy system, as no evidence for a human homolog
of R2D2 has been provided yet. Rather, the silencing
potency of miR-TAR-3p in vivo paralleled the preferential
accumulation of mature miR-TAR-3p upon Dicer proces-
sing of TAR in vitro. This latter step may thus represent a
novel source of asymmetry between miRNAs comprised
within a pre-miRNA. This observation is reminiscent to
endogenous miRNA duplexes, where the level of mature
miRNA detected is higher than that of its opposite
miRNA
  strand (3). miR-TAR-3p and miR-TAR-5p may
thus qualify as the miRNA and miRNA
  of the duplex,
respectively.
HIV-1 is known to perturb gene expression program-
ming of infected cells, aﬀecting thousands of genes (36),
which likely conceal key determinants of its pathogenesis.
As a source of regulatory miRNAs, it is tempting to
speculate about a contributory role of the TAR element.
Our results indicate that HIV-1 mRNA transcripts are a
source of regulatory miRNAs that are functionally
competent in RNA silencing processes in vivo. These
ﬁndings can be reconciled with the recent ﬁndings that
Dicer may act as natural anti-HIV-1 host defenses in
human cells (14). We can thus propose a scenario in which
Dicer would interfere with the virus through processing of
its structured RNAs, such as TAR, from which miRNA
by-products could be released and inﬂuence expression of
viral and/or host genes, with a potential impact on viral
replication.
Biosynthesis and action of TAR miRNAs appear to be
guided by the preferential release of miR-TAR-3p along
asymmetrical processing events yielding miR-TAR-
5p-loop as an intermediate RNA species. The lower
eﬃciency of miR-TAR-5p in regulating gene expression
may be inherent to this stepwise maturation process.
Considering that miRNAs are usually expressed at low
levels and that they act in synergy with other miRNAs,
dismissal of a signiﬁcant role for HIV-1 TAR miRNAs of
low abundance would not be prudent. Rather, the
possibility that TAR miRNA expression ultimately
inﬂuences viral replication and/or the eﬃciency of host
antiviral defenses is attractive and warrants further
investigations. Our study provides the molecular basis
Nucleic Acids Research, 2008, Vol. 36, No. 7 2363required for elucidating the impact of TAR miRNAs on
the gene expression programming of HIV-1-infected cells
and for determining their role and importance in viral
pathogenesis.
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